According to news wire sources in Israel, the investment arm of the Chinese state owned China Everbright Group says it is close to signing deals with local firms and will put at least US$100 million into the tech sector.

China Everbright CEO Shuang Chen who recently visited Israel, met with the head of the National Economic Council, Eugene Kandel, and with Director General of the Industry, Trade and Labor Ministry, Sharon Kedmi.

Chen also met with representatives from 25 Israeli technology companies. He told Israel’s The Marker that his company is close to signing its initial investment deals with Israeli companies and also seeks to encourage joint ventures between both countries’ tech sectors. He added that while China Everbright will likely invest directly in Israeli firms, it will also explore opportunities for brokering deals on behalf of outside investors.

“Most of the Chinese investments not in government bonds are in financial institutions in Hong Kong or in natural resources,” said Chen.

“We need to broaden our active collaborations with Israeli companies. We want to ease the way for companies and investors in China to look abroad and not fear investing. Chinese industry needs to adapt to today’s conditions and incorporate more technology. On the other hand, Israeli companies can benefit from the distribution channels of Chinese companies to reach immense markets. This requires cooperation as early as the development stage: Complete buyouts aren’t enough,” Chen said.

China Everbright will pursue investing in two or three of the Israeli companies he saw last week, Chen said. “We are looking to invest in companies in the fields of medicine, agriculture, and clean tech that have reached an advanced stage, companies with a product and sales but still looking for rapid growth,” he said.

SHL Telemedicine Ltd a leading provider and developer of advanced personal telemedicine solutions, announced that it has entered the Indian healthcare market through collaborations with Indian hospitals.

SHL has signed the first of its kind collaboration agreement, with Belle Vue Clinic, a specialty hospital in Kolkata, part of B.M Birla Hospital chain group.

“With cardio vascular diseases (CVD) threatening to become India’s largest cause of death by 2020 and remarkable growth of private healthcare spending, we foresee a tremendous opportunity in providing our services in the Indian market,” commented Erez Alroy, Co-CEO of SHL Telemedicine.

“SHL will focus first on tier I cities with an aggregate population size of over 60 million where the fast growing urban middle class is experiencing rapid growth of income coupled with modernisation of lifestyle also leading to increased risk of CVD. We expect to generate US$1-5 million from each such collaboration over the course of three years and to sign a series of additional, similar in nature, long term agreements with hospitals,” Alroy added.

SHL says that CVD has risen four-fold in the past 40 years, and cites a World Health Organisation study, which states by 2020, killing 2.6 million people, half of whom will be aged 30-69, will have died.